Blog

The Role of Enhanced Due Diligence in Pharma M&A

Mergers and acquisitions in the life sciences sector can rapidly expand a company’s scientific capabilities, geographic reach, and market access — but[...]
Blog

Navigating the New BIS Landscape: Why a Risk-Based Approach Matters More Than Ever

The U.S. Department of Commerce’s Bureau of Industry and Security (BIS) has long used the Entity List to restrict exports to organizations and individuals engaged in activities contrary to U.S. [...]
Blog

Trade, Tariffs, and Terrorism Webinar Takeaways

Global trade has always been complex but in 2025, the pace and unpredictability of change have reached new heights. From shifting tariff regimes and export controls to new terrorism designations.[...]
Blog

The Business Case for Modern Slavery and Human Rights Compliance in Australia

Australia’s Modern Slavery Act 2018 (Cth) requires thousands of companies to report annually on how they identify and manage risks of modern slavery in their operations and supply chains.[...]
Blog

What the new BIS 50% Rule Means for Third-Party Screening & Ownership Due Diligence

On September 29, 2025, the Bureau of Industry and Security of the US Department of Commerce (“BIS”) issued a new interim final rule [...]
Blog

The Importance of TPRM in Facilitating Ethical Transactions with HCPs

In the Life Sciences industry, maintaining ethical and transparent relationships with healthcare professionals (HCPs) is fundamental to trust, patient safety, and business integrity. [...]
See all Resources